Intervention Review

You have free access to this content

Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer

  1. Theresa A Lawrie1,*,
  2. Roy Rabbie2,
  3. Clemens Thoma3,
  4. Jo Morrison4

Editorial Group: Cochrane Gynaecological Cancer Group

Published Online: 21 OCT 2013

Assessed as up-to-date: 14 AUG 2013

DOI: 10.1002/14651858.CD010482.pub2


How to Cite

Lawrie TA, Rabbie R, Thoma C, Morrison J. Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer. Cochrane Database of Systematic Reviews 2013, Issue 10. Art. No.: CD010482. DOI: 10.1002/14651858.CD010482.pub2.

Author Information

  1. 1

    Royal United Hospital, Cochrane Gynaecological Cancer Group, Bath, UK

  2. 2

    Epsom and St Helier University Hospitals NHS Trust, Department of Respiratory Medicine, London, UK

  3. 3

    University of Oxford, Nuffield Department of Obstetrics & Gynaecology, Oxford, UK

  4. 4

    Musgrove Park Hospital, Department of Obstetrics and Gynaecology, Taunton, Somerset, UK

*Theresa A Lawrie, Cochrane Gynaecological Cancer Group, Royal United Hospital, Education Centre, Bath, BA13NG, UK. tess@lawrie.com.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 21 OCT 2013

SEARCH

[Figure 1]
Figure 1. Study flow diagram of searches to February 2013.
[Analysis 1.1]
Analysis 1.1. Comparison 1 PLD combination versus PAC/carbo, Outcome 1 PFS.
[Analysis 1.2]
Analysis 1.2. Comparison 1 PLD combination versus PAC/carbo, Outcome 2 OS.
[Analysis 1.3]
Analysis 1.3. Comparison 1 PLD combination versus PAC/carbo, Outcome 3 PFS: subgroup analyses.
[Analysis 1.4]
Analysis 1.4. Comparison 1 PLD combination versus PAC/carbo, Outcome 4 OS: subgroup analyses.
[Analysis 1.5]
Analysis 1.5. Comparison 1 PLD combination versus PAC/carbo, Outcome 5 Febrile neutropenia (grade 3/4).
[Analysis 1.6]
Analysis 1.6. Comparison 1 PLD combination versus PAC/carbo, Outcome 6 Neutropenia (grade 3/4).
[Analysis 1.7]
Analysis 1.7. Comparison 1 PLD combination versus PAC/carbo, Outcome 7 Anaemia (grade 3/4).
[Analysis 1.8]
Analysis 1.8. Comparison 1 PLD combination versus PAC/carbo, Outcome 8 Thrombocytopenia (grade 3/4).
[Analysis 1.9]
Analysis 1.9. Comparison 1 PLD combination versus PAC/carbo, Outcome 9 Alopecia (grade 2).
[Analysis 1.10]
Analysis 1.10. Comparison 1 PLD combination versus PAC/carbo, Outcome 10 Vomiting (grade 3/4).
[Analysis 1.11]
Analysis 1.11. Comparison 1 PLD combination versus PAC/carbo, Outcome 11 Stomatitis (grade 3/4).
[Analysis 1.12]
Analysis 1.12. Comparison 1 PLD combination versus PAC/carbo, Outcome 12 Hand-foot syndrome (grade 3/4).
[Analysis 1.13]
Analysis 1.13. Comparison 1 PLD combination versus PAC/carbo, Outcome 13 Neuropathy (grade 3/4).
[Analysis 1.14]
Analysis 1.14. Comparison 1 PLD combination versus PAC/carbo, Outcome 14 Allergic reaction (grade 3/4).
[Analysis 1.15]
Analysis 1.15. Comparison 1 PLD combination versus PAC/carbo, Outcome 15 Fatigue (grade 3/4).
[Analysis 1.16]
Analysis 1.16. Comparison 1 PLD combination versus PAC/carbo, Outcome 16 Treatment-related death.
[Analysis 1.17]
Analysis 1.17. Comparison 1 PLD combination versus PAC/carbo, Outcome 17 Dose delays.
[Analysis 1.18]
Analysis 1.18. Comparison 1 PLD combination versus PAC/carbo, Outcome 18 Discontinuation due to toxicity or refusal.